Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

被引：22

作者：

Qualls, David A.

Lambert, Nicholas ^{[1
,2
]}

Caimi, Paolo F. ^{[3
]}

Merrill, Mwanasha ^{[4
]}

Pullarkat, Priyanka ^{[5
]}

Godby, Richard C. ^{[6
]}

Bond, David A. ^{[6
]}

Wehmeyer, Graham T. ^{[9
,10
]}

Romancik, Jason ^{[11
]}

Amoozgar, Behzad ^{[12
]}

Leslie, Lori ^{[11
]}

Nastoupil, Loretta J. ^{[1
,13
,14
]}

Crombie, Jennifer L. ^{[4
]}

Abramson, Jeremy S. ^{[4
]}

Khurana, Arushi ^{[6
]}

Nowakowski, Grzegorz S. ^{[5
]}

Maddocks, Kami ^{[7
,8
]}

Rutherford, Sarah C. ^{[9
,10
]}

Kahl, Brad ^{[12
]}

Okwali, Michelle ^{[1
]}

Buege, Michael J. ^{[1
]}

Seshan, Venkatraman ^{[1
]}

Batlevi, Connie L. ^{[1
]}

Salles, Gilles ^{[1
,15
,16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Baylor Coll Med, Dept Med, Houston, TX USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA

[6] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Rochester, MN USA

[7] Ohio State Univ, James Canc Hosp, Columbus, OH USA

[8] Ohio State Univ, Solove Res Inst, Columbus, OH USA

[9] Weill Cornell Med, Dept Med, Meyer Canc Ctr, New York, NY USA

[10] New York Presbyterian Hosp, New York, NY USA

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[12] Washington Univ, Sch Med, Dept Med, St Louis, MO USA

[13] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[15] Weill Cornell Med Coll, New York, NY 10065 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

BLOOD | 2023年 / 142卷 / 26期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.2023021274

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL. © 2023 The American Society of Hematology

引用

页码：2327 / 2331

页数：5

共 50 条

[31] Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard- of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Duell, Johannes
Dreyling, Martin
Gaidano, Gianluca
Kalakonda, Nagesh
Gonzalez Barca, Eva Maria
Liberati, Anna Marina
Nagy, Zsolt
Moik, Daniel
Vukcevic, Mirko
Amin, Aasim
Bakuli, Abhishek
BLOOD, 2023, 142
[32] Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
Pirosa, Maria Cristina
Stathis, Anastasios
Zucca, Emanuele
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
[33] Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice
Broccou, Alessandro
Casadei, Beatrice
Chiappella, Annalisa
Visco, Carlo
Tani, Monica
Cascavilla, Nicola
Conconi, Annarita
Balzarotti, Monica
Cox, Maria Christina
Marino, Dario
Goldaniga, Maria Ceolia
Marasca, Roberto
Tecchio, Cristina
Patti, Caterina
Musuraca, Gerardo
Devizzi, Liuana
Monaco, Federico
Romano, Alessandra
Fama, Angelo
Zancanella, Michelle
Paolini, Rossella
Rigacci, Luigi
Castellino, Claudia
Gaudio, Francesco
Argnani, Lisa
Zinzani, Pier Luigi
ONCOLOGIST, 2019, 24 (09): : 1246 - 1252
[34] Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nedved, Adrienne
Maddocks, Kami
Nowakowski, Grzegorz S.
ONCOLOGIST, 2023, : 199 - 207
[35] Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Locke, Frederick L.
Siddiqi, Tanya
Jacobson, Caron A.
Ghobadi, Armin
Ahmed, Sairah
Miklos, David B.
Perales, Miguel -Angel
Munoz, Javier
Fingrut, Warren B.
Pennisi, Martina
Gauthier, Jordan
Shadman, Mazyar
Gowda, Lohith
Mirza, Abu-Sayeef
Abid, Muhammad Bilal
Hong, Sanghee
Majhail, Navneet S.
Kharfan-Dabaja, Mohamed A.
Khurana, Arushi
Badar, Talha
Lin, Yi
Bennani, N. Nora
Herr, Megan M.
Hu, Zhen-Huan
Wang, Hai -Lin
Baer, Anjani
Baro, Elande
Miao, Harry
Spooner, Clare
Xu, Hairong
Pasquini, Marcelo C.
BLOOD, 2024, 143 (26) : 2722 - 2734
[36] Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country
Iftikhar, Raheel
Ahmad, Usman
Haider, Ghulam
Mahmood, Humera
Khan, Maryam
Masood, Misbah
Anwar, Nida
Javed, Qamar
Sajid, Nadia
Tariq, Rija
Mehmod, Sana
Haider, Javeria
Abro, Nargis Aalam
Shahbaz, Shanzah
Khokhar, Abbas
Khan, Zeeshan Ahmed
Pervez, Hassan
Moosajee, Munira
Aziz, Zeba
JCO GLOBAL ONCOLOGY, 2024, 10
[37] Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
Atesoglu, Elif Birtas
Gulbas, Zafer
Uzay, Ant
Ozcan, Muhit
Ozkalemkas, Fahir
Dal, Mehmet Sinan
Kalyon, Hakan
Akay, Olga Meltem
Deveci, Burak
Bekoz, Huseyin
Sevindik, Omur Gokmen
Toptas, Tayfur
Yilmaz, Fergun
Koyun, Derya
Alkis, Nihan
Alacacioglu, Inci
Sonmez, Mehmet
Yavasoglu, Irfan
Tombak, Anil
Mehtap, Ozgur
Kurnaz, Fatih
Yuce, Orhan Kemal
Karakus, Volkan
Turgut, Mehmet
Kurekci, Derya Deniz
Ayer, Mesut
Keklik, Muzaffer
Buyuktas, Deram
Ozbalak, Murat
Ferhanoglu, Burhan
HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 663 - 673
[38] Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia
Costa, S.
Scott, D. W.
Steidl, C.
Peacock, S. J.
Regier, D. A.
CURRENT ONCOLOGY, 2019, 26 (02) : 108 - 113
[39] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
Saverno, Kim
Savill, Kristin M. Zimmerman
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Amoloja, Theresa
Epperla, Narendranath
Nastoupil, Loretta J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
[40] Real-world patient pathway of care for diffuse large B-cell lymphoma (DLBCL).
Yang, Fei
Zhang, Ju
Abraham, Anup
Xiao, Yan
Hammer, Richard D.
Prime, Matthew Stewart
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)

← 1 2 3 4 5 →